S&P 500   3,792.86 (-1.47%)
DOW   30,583.03 (-1.14%)
QQQ   324.95 (-1.11%)
AAPL   143.13 (-0.02%)
MSFT   239.23 (+2.97%)
FB   275.04 (-2.49%)
GOOGL   1,842.96 (-3.41%)
AMZN   3,295.89 (-0.91%)
TSLA   888.57 (+0.62%)
NVDA   523.26 (-2.63%)
BABA   262.54 (-1.27%)
CGC   37.22 (+4.79%)
GE   10.86 (-3.81%)
MU   76.96 (-3.21%)
AMD   90.04 (-4.93%)
NIO   59.58 (-1.21%)
T   30.10 (+1.18%)
F   10.88 (-2.77%)
ACB   11.25 (+5.44%)
BA   197.91 (-2.05%)
DIS   163.51 (-3.57%)
NFLX   543.00 (-3.37%)
GILD   66.08 (-0.93%)
S&P 500   3,792.86 (-1.47%)
DOW   30,583.03 (-1.14%)
QQQ   324.95 (-1.11%)
AAPL   143.13 (-0.02%)
MSFT   239.23 (+2.97%)
FB   275.04 (-2.49%)
GOOGL   1,842.96 (-3.41%)
AMZN   3,295.89 (-0.91%)
TSLA   888.57 (+0.62%)
NVDA   523.26 (-2.63%)
BABA   262.54 (-1.27%)
CGC   37.22 (+4.79%)
GE   10.86 (-3.81%)
MU   76.96 (-3.21%)
AMD   90.04 (-4.93%)
NIO   59.58 (-1.21%)
T   30.10 (+1.18%)
F   10.88 (-2.77%)
ACB   11.25 (+5.44%)
BA   197.91 (-2.05%)
DIS   163.51 (-3.57%)
NFLX   543.00 (-3.37%)
GILD   66.08 (-0.93%)
S&P 500   3,792.86 (-1.47%)
DOW   30,583.03 (-1.14%)
QQQ   324.95 (-1.11%)
AAPL   143.13 (-0.02%)
MSFT   239.23 (+2.97%)
FB   275.04 (-2.49%)
GOOGL   1,842.96 (-3.41%)
AMZN   3,295.89 (-0.91%)
TSLA   888.57 (+0.62%)
NVDA   523.26 (-2.63%)
BABA   262.54 (-1.27%)
CGC   37.22 (+4.79%)
GE   10.86 (-3.81%)
MU   76.96 (-3.21%)
AMD   90.04 (-4.93%)
NIO   59.58 (-1.21%)
T   30.10 (+1.18%)
F   10.88 (-2.77%)
ACB   11.25 (+5.44%)
BA   197.91 (-2.05%)
DIS   163.51 (-3.57%)
NFLX   543.00 (-3.37%)
GILD   66.08 (-0.93%)
S&P 500   3,792.86 (-1.47%)
DOW   30,583.03 (-1.14%)
QQQ   324.95 (-1.11%)
AAPL   143.13 (-0.02%)
MSFT   239.23 (+2.97%)
FB   275.04 (-2.49%)
GOOGL   1,842.96 (-3.41%)
AMZN   3,295.89 (-0.91%)
TSLA   888.57 (+0.62%)
NVDA   523.26 (-2.63%)
BABA   262.54 (-1.27%)
CGC   37.22 (+4.79%)
GE   10.86 (-3.81%)
MU   76.96 (-3.21%)
AMD   90.04 (-4.93%)
NIO   59.58 (-1.21%)
T   30.10 (+1.18%)
F   10.88 (-2.77%)
ACB   11.25 (+5.44%)
BA   197.91 (-2.05%)
DIS   163.51 (-3.57%)
NFLX   543.00 (-3.37%)
GILD   66.08 (-0.93%)
Log in
NASDAQ:FGEN

FibroGen News Headlines

$48.22
-0.77 (-1.57 %)
(As of 01/27/2021 11:15 AM ET)
Add
Compare
Today's Range
$47.30
Now: $48.22
$48.60
50-Day Range
$37.09
MA: $41.24
$49.59
52-Week Range
$22.65
Now: $48.22
$51.56
Volume15,996 shs
Average Volume720,512 shs
Market Capitalization$4.39 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.59

Headlines

FibroGen (NASDAQ FGEN) News Headlines Today

Source:
SourceHeadline
Elizabeth Yeu, M.D. and K. Peony Yu, M.D. Appointed to STAAR Surgical Board of Directors - Business WireElizabeth Yeu, M.D. and K. Peony Yu, M.D. Appointed to STAAR Surgical Board of Directors - Business Wire
businesswire.com - January 26 at 2:26 PM
FibroGen (NASDAQ:FGEN) Stock Price Up 6.6%FibroGen (NASDAQ:FGEN) Stock Price Up 6.6%
americanbankingnews.com - January 22 at 7:39 PM
FibroGen (NASDAQ:FGEN) Stock Price Up 9.4%FibroGen (NASDAQ:FGEN) Stock Price Up 9.4%
americanbankingnews.com - January 14 at 8:26 PM
FGEN Crosses Above Key Moving Average LevelFGEN Crosses Above Key Moving Average Level
nasdaq.com - January 14 at 6:32 PM
FibroGen (NASDAQ:FGEN) Stock Crosses Below Fifty Day Moving Average of $40.40FibroGen (NASDAQ:FGEN) Stock Crosses Below Fifty Day Moving Average of $40.40
americanbankingnews.com - January 12 at 6:22 AM
FibroGen: Roxadustats U.S. Approval, 2020 China Sales, And Outsized Growth - Seeking AlphaFibroGen: Roxadustat's U.S. Approval, 2020 China Sales, And Outsized Growth - Seeking Alpha
seekingalpha.com - December 24 at 7:10 PM
Who Has Been Buying FibroGen, Inc. (NASDAQ:FGEN) Shares? - Yahoo FinanceWho Has Been Buying FibroGen, Inc. (NASDAQ:FGEN) Shares? - Yahoo Finance
finance.yahoo.com - December 23 at 12:16 PM
Who Has Been Buying FibroGen, Inc. (NASDAQ:FGEN) Shares?Who Has Been Buying FibroGen, Inc. (NASDAQ:FGEN) Shares?
finance.yahoo.com - December 23 at 12:16 PM
Dosing underway in FibroGens late-stage pamrevlumab study in chronic lung disease - Seeking AlphaDosing underway in FibroGen's late-stage pamrevlumab study in chronic lung disease - Seeking Alpha
seekingalpha.com - December 22 at 5:46 PM
Why FibroGen Got Mashed on Monday - Motley FoolWhy FibroGen Got Mashed on Monday - Motley Fool
fool.com - December 22 at 12:45 PM
FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2 - GlobeNewswireFibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2 - GlobeNewswire
globenewswire.com - December 22 at 7:45 AM
FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2
finance.yahoo.com - December 22 at 7:45 AM
Why FibroGen Got Mashed on MondayWhy FibroGen Got Mashed on Monday
finance.yahoo.com - December 21 at 7:54 PM
After nearly $1 billion and 27 years, S.F. biotech now must wait another 90 days for 1st FDA decision - San Francisco Business TimesAfter nearly $1 billion and 27 years, S.F. biotech now must wait another 90 days for 1st FDA decision - San Francisco Business Times
bizjournals.com - December 21 at 2:53 PM
AstraZeneca (AZN) announces update on US regulatory review of roxadustat - StreetInsider.comAstraZeneca (AZN) announces update on US regulatory review of roxadustat - StreetInsider.com
streetinsider.com - December 21 at 9:53 AM
AstraZeneca Says FDA Extends Review Period Of FibroGens Anaemia Drug Roxadustat By Three Months - NasdaqAstraZeneca Says FDA Extends Review Period Of FibroGen's Anaemia Drug Roxadustat By Three Months - Nasdaq
nasdaq.com - December 21 at 9:53 AM
FibroGen’s action date for Roxadustat postponed - Seeking AlphaFibroGen’s action date for Roxadustat postponed - Seeking Alpha
seekingalpha.com - December 20 at 12:23 AM
After 20 years and founders sudden death, S.F. biotech wins 1st FDA drug approval - San Francisco Business TimesAfter 20 years and founder's sudden death, S.F. biotech wins 1st FDA drug approval - San Francisco Business Times
bizjournals.com - December 19 at 9:23 AM
Four years after grabbing shelved drug, Peninsula company wins FDA approval in prostate cancer - San Francisco Business TimesFour years after grabbing shelved drug, Peninsula company wins FDA approval in prostate cancer - San Francisco Business Times
bizjournals.com - December 18 at 7:12 PM
FibroGen Provides Regulatory Update on Roxadustat Nasdaq:FGEN - GlobeNewswireFibroGen Provides Regulatory Update on Roxadustat Nasdaq:FGEN - GlobeNewswire
globenewswire.com - December 18 at 7:12 PM
FibroGen Provides Regulatory Update on RoxadustatFibroGen Provides Regulatory Update on Roxadustat
finance.yahoo.com - December 18 at 7:12 PM
First Week of February 2021 Options Trading For FibroGen (FGEN) - NasdaqFirst Week of February 2021 Options Trading For FibroGen (FGEN) - Nasdaq
nasdaq.com - December 18 at 2:12 PM
Notable Friday Option Activity: FEYE, FGEN, DDNotable Friday Option Activity: FEYE, FGEN, DD
nasdaq.com - December 11 at 6:55 PM
FibroGen Announces Retirement of K. Peony Yu, M.D., and Appointment of Mark Eisner, M.D., M.P.H. as Chief Medical Officer - Yahoo FinanceFibroGen Announces Retirement of K. Peony Yu, M.D., and Appointment of Mark Eisner, M.D., M.P.H. as Chief Medical Officer - Yahoo Finance
finance.yahoo.com - December 3 at 2:21 AM
FibroGen to Present Safety and Efficacy Analyses from Roxadustat Global Phase 3 Program at American Society of Hematology Annual Meeting - GlobeNewswireFibroGen to Present Safety and Efficacy Analyses from Roxadustat Global Phase 3 Program at American Society of Hematology Annual Meeting - GlobeNewswire
globenewswire.com - December 2 at 8:47 AM
Two local biotechs harvest top-level execs from Genentech - San Francisco Business TimesTwo local biotechs harvest top-level execs from Genentech - San Francisco Business Times
bizjournals.com - December 1 at 10:46 PM
FibroGen Announces Retirement of K. Peony Yu, M.D., and Appointment of Mark Eisner, M.D., M.P.H. as Chief Medical Officer - GlobeNewswireFibroGen Announces Retirement of K. Peony Yu, M.D., and Appointment of Mark Eisner, M.D., M.P.H. as Chief Medical Officer - GlobeNewswire
globenewswire.com - December 1 at 4:55 PM
FibroGen Announces Retirement of K. Peony Yu, M.D., and Appointment of Mark Eisner, M.D., M.P.H. as Chief Medical OfficerFibroGen Announces Retirement of K. Peony Yu, M.D., and Appointment of Mark Eisner, M.D., M.P.H. as Chief Medical Officer
finance.yahoo.com - December 1 at 4:55 PM
FibroGens (FGEN) Evrenzo Approved in Japan for Another Indication - NasdaqFibroGen's (FGEN) Evrenzo Approved in Japan for Another Indication - Nasdaq
nasdaq.com - November 30 at 5:09 PM
FibroGens (FGEN) Evrenzo Approved in Japan for Another IndicationFibroGen's (FGEN) Evrenzo Approved in Japan for Another Indication
finance.yahoo.com - November 30 at 5:09 PM
FibroGen Gains Japanese Approval for Roxadustat; Mizuho Securities Sees 79% Upside - NasdaqFibroGen Gains Japanese Approval for Roxadustat; Mizuho Securities Sees 79% Upside - Nasdaq
nasdaq.com - November 29 at 9:24 PM
FibroGen Gains Japanese Approval for Roxadustat; Mizuho Securities Sees 79% Upside - Yahoo FinanceFibroGen Gains Japanese Approval for Roxadustat; Mizuho Securities Sees 79% Upside - Yahoo Finance
finance.yahoo.com - November 29 at 4:24 PM
FibroGen Gains Japanese Approval for Roxadustat; Mizuho Securities Sees 79% UpsideFibroGen Gains Japanese Approval for Roxadustat; Mizuho Securities Sees 79% Upside
finance.yahoo.com - November 29 at 4:24 PM
Astellas Pharma and FibroGens roxadustat Okd in Japan for renal anemia - Seeking AlphaAstellas Pharma and FibroGen's roxadustat Ok'd in Japan for renal anemia - Seeking Alpha
seekingalpha.com - November 27 at 5:29 PM
FibroGen Breaks Below 200-Day Moving Average - Notable for FGEN - NasdaqFibroGen Breaks Below 200-Day Moving Average - Notable for FGEN - Nasdaq
nasdaq.com - November 20 at 8:38 PM
FibroGen Breaks Below 200-Day Moving Average - Notable for FGEN - NasdaqFibroGen Breaks Below 200-Day Moving Average - Notable for FGEN - Nasdaq
nasdaq.com - November 20 at 8:38 PM
FibroGen, Inc. Beat Analyst Profit Forecasts, And Analysts Have New EstimatesFibroGen, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
nasdaq.com - November 8 at 1:51 PM
FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q3 2020 Results - Earnings Call TranscriptFibroGen, Inc. (FGEN) CEO Enrique Conterno on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 8 at 1:51 PM
FibroGen, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates - Yahoo FinanceFibroGen, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates - Yahoo Finance
finance.yahoo.com - November 8 at 8:50 AM
FibroGen, Inc. Just Reported A Surprise Profit And Analysts Updated Their EstimatesFibroGen, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates
finance.yahoo.com - November 8 at 8:50 AM
FibroGen (FGEN) Q3 Earnings Beat Estimates - Yahoo FinanceFibroGen (FGEN) Q3 Earnings Beat Estimates - Yahoo Finance
finance.yahoo.com - November 6 at 11:05 PM
FibroGen Inc (FGEN) Q3 2020 Earnings Call Transcript - Motley FoolFibroGen Inc (FGEN) Q3 2020 Earnings Call Transcript - Motley Fool
fool.com - November 6 at 6:04 PM
FibroGen: 3Q Earnings Snapshot - Yahoo FinanceFibroGen: 3Q Earnings Snapshot - Yahoo Finance
finance.yahoo.com - November 6 at 8:02 AM
FibroGen (FGEN) Q3 Earnings Beat Estimates - NasdaqFibroGen (FGEN) Q3 Earnings Beat Estimates - Nasdaq
nasdaq.com - November 6 at 8:02 AM
FibroGen, Inc. to Host Earnings Call - Yahoo FinanceFibroGen, Inc. to Host Earnings Call - Yahoo Finance
finance.yahoo.com - November 5 at 7:55 PM
FibroGen Reports Third Quarter 2020 Financial Results Nasdaq:FGEN - GlobeNewswireFibroGen Reports Third Quarter 2020 Financial Results Nasdaq:FGEN - GlobeNewswire
globenewswire.com - November 5 at 7:55 PM
FibroGen, Inc. to Host Earnings CallFibroGen, Inc. to Host Earnings Call
finance.yahoo.com - November 5 at 7:55 PM
FibroGen Reports Third Quarter 2020 Financial ResultsFibroGen Reports Third Quarter 2020 Financial Results
finance.yahoo.com - November 5 at 7:55 PM
FibroGen (FGEN) Q3 Earnings Beat EstimatesFibroGen (FGEN) Q3 Earnings Beat Estimates
finance.yahoo.com - November 5 at 7:55 PM
FibroGen Q3 2020 Earnings Preview - Seeking AlphaFibroGen Q3 2020 Earnings Preview - Seeking Alpha
seekingalpha.com - November 4 at 1:15 PM
This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.